177Lu-PSMA-617 in the Treatment of Castration-Resistant Prostate Cancer: Experience in Uruguay

Introduction: Prostate cancer is the most frequent solid neoplasm in the world, ranking first in incidence and mortality in Uruguayan men. Despite recent therapeutic advances, metastatic-Castration-Resistant-Prostate-Cancer (mCRPC) remains invariably fatal. Long before 177Lutetium-PSMA radio-directed therapy was approved by the FDA (03/2022), Uruguay already had this technology available for this group of patients. To assess the therapeutic response and safety profile of 177Lu-PSMA-617 in the treatment of mCRPC-patients.